Innoviva Gross Margin 2010-2023 | INVA
Current and historical gross margin for Innoviva (INVA) over the last 10 years. The current gross profit margin for Innoviva as of December 31, 2023 is %.
| Innoviva Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2023-12-31 |
$0.31B |
$0.27B |
86.45% |
| 2023-09-30 |
$0.29B |
$0.25B |
86.55% |
| 2023-06-30 |
$0.29B |
$0.26B |
88.97% |
| 2023-03-31 |
$0.32B |
$0.29B |
92.74% |
| 2022-12-31 |
$0.33B |
$0.32B |
96.07% |
| 2022-09-30 |
$0.37B |
$0.37B |
99.20% |
| 2022-06-30 |
$0.40B |
$0.40B |
100.00% |
| 2022-03-31 |
$0.40B |
$0.40B |
100.00% |
| 2021-12-31 |
$0.39B |
$0.39B |
100.00% |
| 2021-09-30 |
$0.38B |
$0.38B |
100.00% |
| 2021-06-30 |
$0.37B |
$0.37B |
100.00% |
| 2021-03-31 |
$0.34B |
$0.34B |
100.00% |
| 2020-12-31 |
$0.34B |
$0.34B |
100.00% |
| 2020-09-30 |
$0.32B |
$0.32B |
100.00% |
| 2020-06-30 |
$0.30B |
$0.30B |
100.00% |
| 2020-03-31 |
$0.29B |
$0.29B |
100.00% |
| 2019-12-31 |
$0.26B |
$0.26B |
100.00% |
| 2019-09-30 |
$0.27B |
$0.27B |
100.00% |
| 2019-06-30 |
$0.26B |
$0.26B |
100.00% |
| 2019-03-31 |
$0.26B |
$0.26B |
100.00% |
| 2018-12-31 |
$0.26B |
$0.26B |
100.00% |
| 2018-09-30 |
$0.25B |
$0.25B |
100.00% |
| 2018-06-30 |
$0.24B |
$0.24B |
100.00% |
| 2018-03-31 |
$0.23B |
$0.23B |
100.00% |
| 2017-12-31 |
$0.22B |
$0.22B |
100.00% |
| 2017-09-30 |
$0.19B |
$0.19B |
100.00% |
| 2017-06-30 |
$0.18B |
$0.18B |
100.00% |
| 2017-03-31 |
$0.15B |
$0.15B |
100.00% |
| 2016-12-31 |
$0.13B |
$0.13B |
100.00% |
| 2016-09-30 |
$0.11B |
$0.11B |
100.00% |
| 2016-06-30 |
$0.09B |
$0.09B |
100.00% |
| 2016-03-31 |
$0.07B |
$0.07B |
100.00% |
| 2015-12-31 |
$0.06B |
$0.06B |
100.00% |
| 2015-09-30 |
$0.04B |
$0.04B |
100.00% |
| 2015-06-30 |
$0.03B |
$0.03B |
100.00% |
| 2015-03-31 |
$0.02B |
$0.02B |
100.00% |
| 2014-12-31 |
$0.01B |
$0.01B |
100.00% |
| 2014-09-30 |
$0.00B |
$0.00B |
100.00% |
| 2014-06-30 |
$0.00B |
$0.00B |
100.00% |
| 2014-03-31 |
$0.00B |
$0.00B |
100.00% |
| 2013-12-31 |
$0.00B |
$0.00B |
100.00% |
| 2013-09-30 |
$0.01B |
$0.01B |
100.00% |
| 2013-06-30 |
$0.01B |
$0.01B |
100.00% |
| 2013-03-31 |
$0.01B |
$0.01B |
100.00% |
| 2012-12-31 |
$0.14B |
$0.14B |
100.00% |
| 2012-09-30 |
$0.13B |
$0.13B |
100.00% |
| 2012-06-30 |
$0.14B |
$0.14B |
100.00% |
| 2012-03-31 |
$0.14B |
$0.14B |
100.00% |
| 2011-12-31 |
$0.02B |
$0.02B |
100.00% |
| 2011-09-30 |
$0.03B |
$0.03B |
100.00% |
| 2011-06-30 |
$0.02B |
$0.02B |
100.00% |
| 2011-03-31 |
$0.02B |
$0.02B |
100.00% |
| 2010-12-31 |
$0.02B |
$0.02B |
100.00% |
| 2010-09-30 |
$0.02B |
$0.02B |
100.00% |
| 2010-06-30 |
$0.02B |
$0.02B |
100.00% |
| 2010-03-31 |
$0.02B |
$0.02B |
100.00% |
| 2009-12-31 |
$0.03B |
$0.03B |
100.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$0.959B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
